Ignis Therapeutics

BiotechnologySeries AShanghai, China

Latest round

Series A

Last raised

Jan 2023

Total raised

$183M

Investors

7

About Ignis Therapeutics

Based in Shanghai, China and founded in 2020, Ignis Therapeutics is a developer of innovative therapies for the central nervous system. The company's CEO Dr. Aijing Long once serves as general manager of Sanofi. Ignis Therapeutics has a strategic cooperation with SK Biopharmaceuticals. The company's product Cenobamate is an innovative antiepileptic drug. And Solrimfetol is used to treat excessive daytime sleepiness (EDS) caused by narcolepsy or obstructive sleep apnea (OSA). Ignis Therapeutics also has licensing rights to six innovative drugs including Cenobamate and Solriamfetol.

Who invested in Ignis Therapeutics

7 investors across 2 rounds

See all investors in Ignis Therapeutics

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Series A

    Jan 20, 2023

    Amount

    $2.8M

    Investors

    Locked

  2. Series A

    Nov 11, 2021

    Amount

    $180M

    Investors

    Locked

Questions about Ignis Therapeutics

Who invested in Ignis Therapeutics?

Ignis Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Ignis Therapeutics raised?

Ignis Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.

When did Ignis Therapeutics last raise money?

Ignis Therapeutics's most recent round on record is a Series A, in Jan 2023.

What does Ignis Therapeutics do?

Based in Shanghai, China and founded in 2020, Ignis Therapeutics is a developer of innovative therapies for the central nervous system.

Where is Ignis Therapeutics headquartered?

Ignis Therapeutics is headquartered in Shanghai, China.

Which VCs invest in companies like Ignis Therapeutics?

Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Ignis Therapeutics's stage. Their profiles are linked below.

Raising like Ignis Therapeutics? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.